melanoma
Showing NaN - NaN of 74
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma Trial in United States (Tegavivint)
Recruiting
- Colorectal Carcinoma
- +21 more
- Dual X-ray Absorptiometry
- +2 more
-
Birmingham, Alabama
- +18 more
Jan 30, 2023
Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab)
Recruiting
- Melanoma
- Pembrolizumab
- +5 more
-
Los Angeles, California
- +39 more
Jan 25, 2023
Melanoma Trial in Worldwide (Pembrolizumab, Vibostolimab, V937)
Recruiting
- Melanoma
- Pembrolizumab
- +5 more
-
Los Angeles, California
- +28 more
Jan 25, 2023
Melanoma Trial in Worldwide (Pembrolizumab, Quavonlimab, Vibostolimab)
Recruiting
- Melanoma
- Pembrolizumab
- +4 more
-
Los Angeles, California
- +34 more
Jan 25, 2023
Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC Trial in Australia, United States (RO7502175, Atezolizumab)
Recruiting
- Locally Advanced or Metastatic Solid Tumors
- +10 more
-
Aurora, Colorado
- +6 more
Jan 4, 2023
Melanoma, Lymphoma, Solid Tumor Trial in Worldwide (Pembrolizumab)
Recruiting
- Melanoma
- +4 more
- Pembrolizumab
-
Aurora, Colorado
- +18 more
Jan 5, 2023
Ovarian Cancer, Cervical Cancer, Endometrial Cancer Trial in Worldwide (Enapotamab vedotin (HuMax-AXL-ADC))
Completed
- Ovarian Cancer
- +7 more
- Enapotamab vedotin (HuMax-AXL-ADC)
-
Phoenix, Arizona
- +40 more
Dec 12, 2022
Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)
Active, not recruiting
- Melanoma
- +7 more
- Autogene cevumeran
- Atezolizumab
-
Scottsdale, Arizona
- +36 more
Dec 22, 2022
Melanoma Trial in Worldwide (Dabrafenib, Trametinib, Placebos)
Melanoma Trial in Worldwide (Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination)
Recruiting
- Melanoma
- Nivolumab
- Nivolumab + Relatlimab Fixed Dose Combination
-
Birmingham, Alabama
- +185 more
Dec 3, 2022
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer Trial in United States (Ulixertinib (BVD-523))
Available
- Pancreatic Cancer
- +20 more
- Ulixertinib (BVD-523)
-
Birmingham, Alabama
- +25 more
Nov 4, 2022
Melanoma Trial in Worldwide (Pembrolizumab, Placebo)
Active, not recruiting
- Melanoma
- Pembrolizumab
- Placebo
-
Tucson, Arizona
- +158 more
Oct 31, 2022
Improving Adolescent and Young Adult Self-Reported Data in
Recruiting
- Breast Cancer, NOS
- +11 more
- Questionnaires
-
Fairbanks, Alaska
- +313 more
Sep 20, 2022
Melanoma Trial in Aurora (VESANOID, Ipilimumab)
Active, not recruiting
- Melanoma
-
Aurora, ColoradoUniversity of Colorado Hospital
Sep 7, 2022
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases Trial in United States (Botensilimab, Balstilimab)
Recruiting
- Advanced Cancer
- +7 more
-
Scottsdale, Arizona
- +14 more
Sep 15, 2022
Melanoma Trial in Australia, United States (mRNA-4157, Pembrolizumab)
Active, not recruiting
- Melanoma
- mRNA-4157
- Pembrolizumab
-
Tucson, Arizona
- +21 more
Aug 23, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Melanoma Trial in Worldwide (Pembrolizumab, Pembrolizumab/Quavonlimab, Lenvatinib)
Recruiting
- Melanoma
- Pembrolizumab
- +2 more
-
Los Angeles, California
- +28 more
Aug 12, 2022
Melanoma, Solid Tumor Trial in Korea, Republic of, Spain, United States (DAY101, Pimasertib Hydrochloride)
Recruiting
- Melanoma
- Solid Tumor
- DAY101
- Pimasertib Hydrochloride
-
Los Angeles, California
- +13 more
Jul 27, 2022